The prevalence of use, dependency and harms of legal ‘party pills’ containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand

References

• Aitchison L., Hughes R. Treatment of adolescent rats with 1‐benzylpiperazine: a preliminary study of subsequent behavioral effects. Neurotoxicology and Teratology 2006; 28: 453–458
   PubMed Web of Science ®Google Scholar
• Alansari M., Hamilton D. Nephrotoxicity of BZP‐based herbal party pills: a New Zealand case report. New Zealand Medical Journal 2006; 119: 1959
   Google Scholar
• Austin H., Monasterio E. Acute psychosis following ingestion of ‘Rapture’. Australasian Psychiatry 2004; 12: 406–408
   PubMedGoogle Scholar
• Baumann M., Clark R., Budzynski A., Partilla J., Blough B., Rothman K. Effects of ‘Legal X’ piperazine analogs on dopamine and serotonin release in rat brain. Annals of the New York Academy of Sciences 2004; 1025: 189–197
   PubMed Web of Science ®Google Scholar
• Baumann M., Clark R., Budzynski A., Partilla J., Blough B., Rothman K. N‐substituted piperazines abused by humans mimic the molecular mechanism of 3,4‐methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology 2005; 30: 550–560
   PubMed Web of Science ®Google Scholar
• Blundell S. Pop until you drop. New Zealand Listener 2005; 199, June 11–17
   Google Scholar
• Bye C., Munro‐Faure A., Peck A., Young P. A comparison of the effects of l‐benzylpiperazine on human performance tests. European Journal of Clinical Pharmacology 1973; 6: 163–169
   PubMed Web of Science ®Google Scholar
• Campbell H., Cline W., Evans M., et al. Comparison of the effects of dexamethamphetamine and l‐benzylpiperazine in former addicts. European Journal of Clinical Pharmacology 1973; 6: 170–176
   PubMed Web of Science ®Google Scholar
• de Boer D., Bosman I., Hidvegi E., Manzoni C., Benko A., dos Reys J., Maes R. Piperazine‐like compounds: a new group of designer drugs of abuse on the European market. Neuropsychopharmacology 2005; 30: 550–560
   PubMedGoogle Scholar
• Drug Enforcement Administration (DEA) Department of Justice. Schedules of controlled substances; placement of 2,5‐dimethoxy‐4‐(n)‐propylthiophenethylamine and N‐benzylpiperazine into Schedule I of the Controlled Substances Act. Final rune., Federal Register. 69. 12794–12797
   Google Scholar
• Expert Advisory Committee on Drugs. The Expert Advisory Committee on Drugs (EACD) Advice to the Minister on: benzylpiperazibe (BZP). Wellington, EACD
   Google Scholar
• Fantegrossi W., Winger G., Woods J., Woolverton W., Coop A. Reinforcing and discriminative stimulus effects of 1‐benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug and Alcohol Dependence 2005; 77: 161–168
   PubMed Web of Science ®Google Scholar
• Gee P., Richardson S., Woltersdorf W., Moore G. Toxic effects of BZP‐based herbal party pills in humans: a prospective study in Christchurch, New Zealand. New Zealand Medical Journal 2005; 118: 1784
   PubMedGoogle Scholar
• Gossop M., Darke S., Griffiths P., Hando J., Powis B., Hall W., Strang J. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607–614
   PubMed Web of Science ®Google Scholar
• Hall W., Hando J. Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug and Alcohol Review 1994; 13: 277–284
   PubMedGoogle Scholar
• Hando J., Topp L., Hall W. Amphetamine‐related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence 1997; 46: 105–113
   PubMed Web of Science ®Google Scholar
• Herndon J., Pierson M., Glennon R. Mechanistic investigation of the stimulus properties of 1‐(3‐trifluoromethylyphenyl)piperazine. Pharmacology Biochemistry and Behavior 1992; 43: 739–748
   PubMed Web of Science ®Google Scholar
• Janes A. Party pills. New Zealand Listener 2004, 23–29 October
   Google Scholar
• Kirby T. Funk pills: getting on a ‘legal high’. Independent 2006, 30 May
   Google Scholar
• Klee H. A typology of amphetamine users in the United Kingdom. Amphetamine misuse: international perspectives on current trends, H Klee. Harwood Academic Publishers, Amsterdam 1997; 35–68
   Google Scholar
• Maurer H., Kraemer T., Springer D., Staack R. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophene types: a synposis. Therapeutic Drug Monitoring 2004; 26: 127–131
   PubMed Web of Science ®Google Scholar
• McCandless D. Clubbers snap up new legal high. Guardian 2005, 13 December
   Google Scholar
• McKetin R., McLaren J., Lubman D., Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101: 1473–1478
   PubMed Web of Science ®Google Scholar
• Meririnne E., Kajos M., Kankaanpaa A., Seppala T. Rewarding properties of 1‐benzylpiperazine, a new drug of abuse, in rats. Basic & Clinical Pharmacology & Toxicology 2006; 98: 346–350
   PubMed Web of Science ®Google Scholar
• Morgan P., Beck J. The legacy and the paradox: hidden contexts of methamphetamine misuse in the United States. Amphetamine misuse: international perspectives on current trends, H Klee. Harwood Academic Publishers, Amsterdam 1997; 135–162
   Google Scholar
• Nicholson T. Prevalence of use, epidemillogy and toxicity of ‘herbal party pills’ among those presenting to the emergency department. Emergency Medicine Australasia 2006; 18: 180–184
   PubMedGoogle Scholar
• Sato M., Chen C., Akiyama K., Otsuki S. Acute exacerbation of paranoid psychotic state after long‐term abstinence in patients with previous methamphetamine psychosis. Biological Psychiatry 1983; 18: 429–440
   PubMed Web of Science ®Google Scholar
• Saunders A. Party pill user set room on fire. Dominion Post 2005, 22 April
   Google Scholar
• Social Tonics Association New Zealand (STANZ). 2004. EACD decision based on evidence and harm minimisation. Press Release, 8 April. Available at: http://www.stanz.org.nz/images/EACD%20decision%20based%20on%20evidence.pdf
   Google Scholar
• Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug and Alcohol Dependence 1999; 55: 105–115
   PubMed Web of Science ®Google Scholar
• Topp L., Mattick R. Choosing a cut‐off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997; 92: 839–845
   PubMed Web of Science ®Google Scholar
• Tsutsumi H., Katagi M., Miki A., Shima N., Kamata T., Nakajima K., Inoue H., Kishi T., Tsuchihashi H. Metabolism and the urinary excretion profile of the recently scheduled designer drug N‐benzlypiperazine (BZP) in the rat. Journal of Analytical Toxicology 2006; 30: 38–43
   PubMed Web of Science ®Google Scholar
• Vince G. Legally high. New Scientist 2006; 191((2571))40–45
   Web of Science ®Google Scholar
• Wikstrom M., Holmgren P., Ahlner J. A2 (N‐benzylpiperazine) a new drug of abuse in Sweden. Journal of Analytical Toxicology 2004; 28: 67–70
   PubMed Web of Science ®Google Scholar
• Yates K., O'Connor A., Horlsey C. ‘Herbal Ecstasy’: a case series of adverse reactions. New Zealand Medical Journal 2000; 113: 315–317
   PubMed Web of Science ®Google Scholar
• Yui K., Goto K., Ikemoto S., Nishijima K., Yoshino T., Ishiguro T. Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis. Drug and Alcohol Dependence 2001; 64: 133–142
   PubMed Web of Science ®Google Scholar